The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).
 
Gonzalo Recondo
Consulting or Advisory Role - Amgen; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Robin Guo
No Relationships to Disclose
 
Paola Cravero
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Christina Falcon
No Relationships to Disclose
 
Natalie Vokes
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Pfizer
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Giulia Costanza Leonardi
No Relationships to Disclose
 
Giuseppe Lamberti
No Relationships to Disclose
 
Tom Nguyen
No Relationships to Disclose
 
Deepti Venkatraman
No Relationships to Disclose
 
Lynette Marie Sholl
Honoraria - AstraZeneca
Consulting or Advisory Role - Foghorn Therapeutics; Loxo
Research Funding - Roche/Genentech
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)